Inhibition of Drp1, using Mdivi-1 or siDrp1, restored cisplatin sensitivity in hypoxic ovarian cancer cells, indicating that inhibiting fission could be a mitochondrial-targeted anticancer therapy in ovarian cancer [177], as originally proposed in lung cancer [133]. The gene discussed is DNM1L; the disease is lung cancer.